EUVIMEDEUVIMED entdecken
Crossref

Ginsenoside CK regulates non-alcoholic fatty liver disease by regulating liver fat metabolism and gut microbiota

Yifang Xiong, Chenhui Zhu, Yanru Chen, Ru Xu, Rongzhan Fu, Xiaoxuan Ma, Zhiguang Duan

International Immunopharmacology · 2026

DOI: 10.1016/j.intimp.2026.116338 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Yifang Xiong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center of Western Resource Innovation Medicine Green Manufacturing, Ministry of Education, School of Chemical Engineering, North…. Hauptthemen laut MEDLINE: Ginsenosides, Non-alcoholic Fatty Liver Disease, Gastrointestinal Microbiome, Liver. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global incidence of non-alcoholic fatty liver disease (NAFLD) is on a continuous rise, characterized by hepatic lipid metabolism disorder and gut microbiota dysbiosis. Although ginsenoside compound K (CK) exhibits hepatoprotective and anti-inflammatory activities, its specific role in the pathogenesis of NAFLD remains to be fully elucidated. In this study, a high-fat-high-cholesterol (HFHC) diet-induced NAFLD mouse model was used to investigate the protective effects of CK against the disease. The results demonstrated that CK intervention significantly attenuated HFHC diet-induced body weight gain in mice: the body weight of mice in the CK-L group (60 mg/kg) decreased by approximately 11.7%, hepatic inflammation was reduced by about 35%-45%, and lipid deposition was improved by roughly 50%-60%. Mechanistically, CK activates the peroxisome proliferator-activated receptor (PPAR) signaling pathway, regulates the expression of lipid metabolism-related genes and proteins, thereby ameliorating lipid metabolism disorder. Meanwhile, CK reverses HFHC diet-induced gut microbiota dysbiosis, upregulates the abundance of the beneficial bacterium Akkermansia, and modulates the intestinal phylum composition in NAFLD mice by increasing the proportion of Bacteroidetes and decreasing that of Firmicutes. CK regulates the occurrence and development of NAFLD via the gut-liver axis, providing experimental evidence for subsequent mechanistic research on NAFLD prevention and treatment as well as the exploration of candidate drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GinsenosidesNon-alcoholic Fatty Liver DiseaseGastrointestinal MicrobiomeLiverLipid MetabolismAnti-Inflammatory AgentsAnimalsDiet, High-FatMaleMiceDysbiosisDisease Models, AnimalMice, Inbred C57BLHumansPeroxisome Proliferator-Activated ReceptorsSignal Transduction

Stichwörter der Autor:innen

Fat metabolismGinsenoside CKGut microbiotaNonalcoholic fatty liver disease

Substanzen

Ginsenosidesginsenoside compound KPeroxisome Proliferator-Activated ReceptorsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Engineering Research Center of Western Resource Innovation Medicine Green Manufacturing, Ministry of Education, School of Chemical Engineering, Northwest University, Xi'an 710127, China; Biotech. & Biomed. Research Inst…
  • Shaanxi Gaint Biotechnology Co., Ltd, Xi'an 710065, Shaanxi, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xiong, Y., Zhu, C., Chen, Y., Xu, R., Fu, R., Ma, X., & Duan, Z. (2026). Ginsenoside CK regulates non-alcoholic fatty liver disease by regulating liver fat metabolism and gut microbiota. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.116338

Vancouver

Xiong Y, Zhu C, Chen Y, Xu R, Fu R, Ma X, et al. Ginsenoside CK regulates non-alcoholic fatty liver disease by regulating liver fat metabolism and gut microbiota. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.116338

BibTeX
@article{Xiong2026,
  author = {Xiong, Yifang and Zhu, Chenhui and Chen, Yanru and Xu, Ru and Fu, Rongzhan and Ma, Xiaoxuan and Duan, Zhiguang},
  title = {Ginsenoside CK regulates non-alcoholic fatty liver disease by regulating liver fat metabolism and gut microbiota},
  journal = {International Immunopharmacology},
  year = {2026},
  doi = {10.1016/j.intimp.2026.116338}
}
Kostenlos starten →